SCHEMBL6946255

SCHEMBL6946255

COC(=O)C1=C(CCc2ccccc2OCCN2CCCC2=O)NC(CC(=O)N2CCN(C3CC4CCC(C3)N4C)CC2)=C(C(=O)OC)C1c1c(Cl)cccc1Cl

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.33
MEN1 O00255 1/20 0.33
BDKRB1 P46663 1/20 0.31
KDM4E B2RXH2 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
ALOX15 P16050 1/20 0.31
ATM Q13315 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TYRO3 Q06418 4/20 0.31
IDH1 O75874 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
MET P08581 1/20 0.31
SELP P16109 1/20 0.31
AXL P30530 1/20 0.31
MERTK Q12866 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6945576 0.94 POLB (0.34) KMT2AMEN1BDKRB1KDM4EALDH1A1
SCHEMBL6942959 0.90 SIGMAR1 (0.35) KMT2AMEN1BDKRB1SIGMAR1SCD
SCHEMBL6944085 0.89 SIGMAR1 (0.33) KMT2AMEN1BDKRB1SIGMAR1SCD
SCHEMBL7493254 0.88 SIGMAR1 (0.41) KMT2AMEN1BDKRB1KDM4EALDH1A1
SCHEMBL6945511 0.85 KMT2A (0.39) KMT2AMEN1BDKRB1KDM4EUSP2
SCHEMBL6943069 0.84 CCR3 (0.35) KMT2AMEN1BDKRB1KDM4EALDH1A1
SCHEMBL6152139 0.84 CCR3 (0.35) KMT2AMEN1BDKRB1KDM4EALDH1A1
SCHEMBL6943632 0.83 SIGMAR1 (0.35) KMT2AMEN1BDKRB1KDM4EALDH1A1
SCHEMBL6947171 0.83 CCR3 (0.34) BDKRB1KDM4EALDH1A1MAPK1CCR3
SCHEMBL6946815 0.82 CCR3 (0.33) KMT2AMEN1BDKRB1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US claimed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP claimed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US claimed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO claimed
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
EP-1307449-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2003-05-07 EP disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed
WO-2002012235-A1 1,4-DIHYDROPYRIDINES AS BRADYKININ ANTAGONISTS PFIZER PHARMACEUTICALS INC. (JP) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 KMT2A 1890/4885MEN1 2435/4885BDKRB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.